Search
forLearn
5 / 801 resultslearn HT-B
learn ACETYL TETRAPEPTIDE-2
learn PTT-6®
learn vitamin b2
Research
5 / 1000+ results
research IL-33 Contributes to the Pathological Changes of Hair Follicles in Psoriasis: A Potential Target for Psoriatic Alopecia
IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.
research The role of skin macrophages under conditions of stress and injury: ultraviolet irradiation and wound healing
Inhibiting IL-17 and IL-23 improves wound healing in obese, diabetic mice by promoting healing macrophages.
research 毛乳頭細胞と毛包上皮細胞間の細胞内・細胞外情報伝達
3D-oxy exosomes may significantly boost hair growth, offering new treatment options for hair loss.
research Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
research 212 DISTURBANCES OF REPRODUCTIVE FUNCTION IN WOMEN WITH PITUITARY ADENOMA
Women with pituitary adenomas often have reproductive issues, like irregular periods and trouble getting pregnant, but not always breast milk production without pregnancy.
Community Join
5 / 1000+ resultscommunity Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community Trestolone (MENT) as a nuclear treatment
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.